Navtemadlin Will Be Evaluated as Add-On Therapy to Ruxolitinib in Myelofibrosis
Navtemadlin will be evaluated as add-on therapy to ruxolitinib in myelofibrosis.
N/A
MY
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- ASH 2024: New Research, Data Drive Progress in Myelofibrosis
- Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors
- Population Pharmacokinetics and Exposure‑Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis
- SOHO 2026: Imetelstat Efficacy in Myelofibrosis - GERN
- Current treatments, practical management, and emerging investigational therapies for myelofibrosis